Urolithin A attenuates pulmonary fibrosis via the PI3K/AKT/mTOR pathway: Evidence from network pharmacology and experimental validation

UA exerts therapeutic effects on PF by targeting the PI3K/AKT/mTOR pathway, particularly through the inhibition of AKT1 phosphorylation. These findings indicate that UA has potential as a therapeutic candidate for PF and provide a novel perspective for utilizing gut microbiota metabolites in the treatment of fibrotic diseases. Further studies are needed to elucidate the precise mechanisms of UA.